Iteos Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

iTeos Therapeutics

10/05/2024 16:11

* Iteos Therapeutics Inc  ITOS.OQ  reported a quarterly
adjusted
loss of $1.07​​ per share for the quarter ended in March, lower
than the same quarter last year, when the company reported EPS
of -44 cents.  The mean expectation of five analysts for the
quarter was for a loss of $1.26 per share. Wall Street expected
results to range from $-2.20 to -86 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Iteos Therapeutics Inc's reported EPS for the quarter was
a loss
of $1.07​.
    * The company reported a quarterly loss of $38.22 million.
    * Iteos Therapeutics Inc shares had fallen by 10.6% this
quarter and gained 11.3% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 11% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Iteos
Therapeutics Inc is $40.00 
This summary was machine generated from LSEG data May 10 at
03:11 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -1.26          -1.07          Beat
 Dec. 31 2023      -1.03          -0.85          Beat
 Sep. 30 2023      -1.20          -0.90          Beat
 Jun. 30 2023      -1.03          -0.96          Beat